Review



cxcl12 elisa kit  (Krishgen Biosystems)


Bioz Verified Symbol Krishgen Biosystems is a verified supplier
Bioz Manufacturer Symbol Krishgen Biosystems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Krishgen Biosystems cxcl12 elisa kit
    Survival and migration of CD34 + cells from TN patients are not increased by pro-inflammatory cytokines. a CD34 + cells from JAK2 V617F ( n = 4) or TN ( n = 4) patients were in vitro treated with combined pro-inflammatory factors such as IL-1β, TNF-α, and IL6 and the fold-change of cell viability was assessed after Annexin V/PI staining, as described in Methods. Dot lines were used to mark control samples without any treatment, as fold-change = 1. b Spontaneous migration and toward <t>CXCL12,</t> alone or in combination with pro-inflammatory cytokines, were observed in JAK2 V617F -derived ( n = 4) CD34 + cells as compared with the TN ( n = 4) counterparts. Results are expressed as mean percentages ± SEM of input (* p ≤ 0.05; ** p ≤ 0.01)
    Cxcl12 Elisa Kit, supplied by Krishgen Biosystems, used in various techniques. Bioz Stars score: 90/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cxcl12 elisa kit/product/Krishgen Biosystems
    Average 90 stars, based on 2 article reviews
    cxcl12 elisa kit - by Bioz Stars, 2026-02
    90/100 stars

    Images

    1) Product Images from "Distinct profile of CD34 + cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease"

    Article Title: Distinct profile of CD34 + cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    doi: 10.1186/s13046-020-01776-8

    Survival and migration of CD34 + cells from TN patients are not increased by pro-inflammatory cytokines. a CD34 + cells from JAK2 V617F ( n = 4) or TN ( n = 4) patients were in vitro treated with combined pro-inflammatory factors such as IL-1β, TNF-α, and IL6 and the fold-change of cell viability was assessed after Annexin V/PI staining, as described in Methods. Dot lines were used to mark control samples without any treatment, as fold-change = 1. b Spontaneous migration and toward CXCL12, alone or in combination with pro-inflammatory cytokines, were observed in JAK2 V617F -derived ( n = 4) CD34 + cells as compared with the TN ( n = 4) counterparts. Results are expressed as mean percentages ± SEM of input (* p ≤ 0.05; ** p ≤ 0.01)
    Figure Legend Snippet: Survival and migration of CD34 + cells from TN patients are not increased by pro-inflammatory cytokines. a CD34 + cells from JAK2 V617F ( n = 4) or TN ( n = 4) patients were in vitro treated with combined pro-inflammatory factors such as IL-1β, TNF-α, and IL6 and the fold-change of cell viability was assessed after Annexin V/PI staining, as described in Methods. Dot lines were used to mark control samples without any treatment, as fold-change = 1. b Spontaneous migration and toward CXCL12, alone or in combination with pro-inflammatory cytokines, were observed in JAK2 V617F -derived ( n = 4) CD34 + cells as compared with the TN ( n = 4) counterparts. Results are expressed as mean percentages ± SEM of input (* p ≤ 0.05; ** p ≤ 0.01)

    Techniques Used: Migration, In Vitro, Staining, Derivative Assay



    Similar Products

    cxcl12 elisa kit  (Krishgen Biosystems)
    90
    Krishgen Biosystems cxcl12 elisa kit
    Survival and migration of CD34 + cells from TN patients are not increased by pro-inflammatory cytokines. a CD34 + cells from JAK2 V617F ( n = 4) or TN ( n = 4) patients were in vitro treated with combined pro-inflammatory factors such as IL-1β, TNF-α, and IL6 and the fold-change of cell viability was assessed after Annexin V/PI staining, as described in Methods. Dot lines were used to mark control samples without any treatment, as fold-change = 1. b Spontaneous migration and toward <t>CXCL12,</t> alone or in combination with pro-inflammatory cytokines, were observed in JAK2 V617F -derived ( n = 4) CD34 + cells as compared with the TN ( n = 4) counterparts. Results are expressed as mean percentages ± SEM of input (* p ≤ 0.05; ** p ≤ 0.01)
    Cxcl12 Elisa Kit, supplied by Krishgen Biosystems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cxcl12 elisa kit/product/Krishgen Biosystems
    Average 90 stars, based on 1 article reviews
    cxcl12 elisa kit - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Survival and migration of CD34 + cells from TN patients are not increased by pro-inflammatory cytokines. a CD34 + cells from JAK2 V617F ( n = 4) or TN ( n = 4) patients were in vitro treated with combined pro-inflammatory factors such as IL-1β, TNF-α, and IL6 and the fold-change of cell viability was assessed after Annexin V/PI staining, as described in Methods. Dot lines were used to mark control samples without any treatment, as fold-change = 1. b Spontaneous migration and toward CXCL12, alone or in combination with pro-inflammatory cytokines, were observed in JAK2 V617F -derived ( n = 4) CD34 + cells as compared with the TN ( n = 4) counterparts. Results are expressed as mean percentages ± SEM of input (* p ≤ 0.05; ** p ≤ 0.01)

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    Article Title: Distinct profile of CD34 + cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease

    doi: 10.1186/s13046-020-01776-8

    Figure Lengend Snippet: Survival and migration of CD34 + cells from TN patients are not increased by pro-inflammatory cytokines. a CD34 + cells from JAK2 V617F ( n = 4) or TN ( n = 4) patients were in vitro treated with combined pro-inflammatory factors such as IL-1β, TNF-α, and IL6 and the fold-change of cell viability was assessed after Annexin V/PI staining, as described in Methods. Dot lines were used to mark control samples without any treatment, as fold-change = 1. b Spontaneous migration and toward CXCL12, alone or in combination with pro-inflammatory cytokines, were observed in JAK2 V617F -derived ( n = 4) CD34 + cells as compared with the TN ( n = 4) counterparts. Results are expressed as mean percentages ± SEM of input (* p ≤ 0.05; ** p ≤ 0.01)

    Article Snippet: In particular, the Human Thrombopoietin Quantikine ELISA Kit was provided from R&D Systems (Minneapolis, Minnesota, USA) and CXCL12 ELISA kit from Krishgen ByoSistems (Ashley CT, Whittier, CA, USA).

    Techniques: Migration, In Vitro, Staining, Derivative Assay